US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

MannKind Corporation - Common Stock (NQ:MNKD)

3.800 -0.150 (-3.80%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum ↗
MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major... 
Via MarketBeat
News headline image
MannKind Q2 Earnings Call Highlights ↗
MannKind (NASDAQ:MNKD) reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased... 
Via MarketBeat
Topics Earnings
MannKind (NASDAQ:MNKD) Falls as Q2 EPS Miss Overshadows In-Line Revenue ↗
Via Chartmill
News headline image
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway ↗
MannKind (NASDAQ:MNKD) reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study... 
Via MarketBeat
MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress ↗
Via Chartmill
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 ↗
Via Chartmill
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
Via Stocktwits
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? ↗
Via Stocktwits
News headline image
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE ↗
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds... 
Via MarketBeat
News headline image
What This MannKind Filing Reveals About Three Years of Underperformance ↗
Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk ↗
Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index. 
Via The Motley Fool
Topics Regulatory Compliance
MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗
Via Stocktwits
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗
Via Stocktwits
News headline image
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million ↗
This disposition was tied to vesting of performance-based RSUs at 83% of the target. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk ↗
Tross disposed of 65,808 shares to cover tax withholding from a vested performance award, retaining over 1 million shares in the company. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? ↗
Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market ↗
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into... 
Via MarketBeat
News headline image
MannKind (MNKD) Q1 2026 Earnings Transcript ↗
MannKind (MNKD) Q1 2026 Earnings Transcript 
Via The Motley Fool
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
What's Going On With MannKind Stock Friday? ↗
MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations. 
Via Benzinga
News headline image
Why MannKind Stock Tumbled on Thursday ↗
Mr. Market was hoping for a better fourth quarter than the company delivered. 
Via The Motley Fool
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗
United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.” 
Via Stocktwits
Here are the top movers in Wednesday's session. ↗
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus. 
Via Stocktwits
News headline image
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? ↗
This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop ↗
With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year ↗
The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
< Previous 1 2 3 4 5 6 Next >